The Times They Are A-Changin’: New Antibacterials for Skin and Skin Structure Infections
- 24 April 2015
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 16 (3) , 137-146
Abstract
Twenty-one agents are approved by the US Food and Drug Administration (FDA) for the therapy of skin and soft tissue infections. Of these, the five newest agents, tedizolid, telavancin, oritavancin, dalbavancin, and ceftaroline, are active against and “non-inferior” to vancomycin against methicillin-resistant Staphylococcus aureus (MRSA). Oritavancin is indicated as a single-dose intravenous regimen, while dalbavancin is a two-dose intravenous regimen given 1 week apart. Telavancin has multiple mechanisms of action. A 6-day regimen of once-daily intravenous or oral dose of tedizolid was compared with 10 days of linezolid and found to be “non-inferior” and have fewer side effects. Ceftaroline has not only MRSA activity but also activity against Escherichia coli and Klebsiella spp. We review the spectra of activity of these new agents, their clinical trials and their therapeutic efficacy, noting differences in their dosing schedules, in vitro activities and costs as potential determinants for appropriate utilization.Keywords
This publication has 54 references indexed in Scilit:
- In Vitro , In Vivo , and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase InteractionsAntimicrobial Agents and Chemotherapy, 2013
- In Vitro Activity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2012
- Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five ContinentsAntimicrobial Agents and Chemotherapy, 2012
- Activity of Ceftaroline and Epidemiologic Trends in Staphylococcus aureus Isolates Collected from 43 Medical Centers in the United States in 2009Antimicrobial Agents and Chemotherapy, 2011
- Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI TrialAntimicrobial Agents and Chemotherapy, 2011
- Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2011
- Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive PathogensClinical Infectious Diseases, 2011
- Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or BacteremiaAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial AgentAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant StrainsAntimicrobial Agents and Chemotherapy, 2008